SARS-CoV-2 Vaccine Constructs
AssigneeRutgers, The State University of New Jersey
InventorsStephen Anderson, Elliot Campbell
Life of this patent
Estimating the term…
Abstract
The present disclosure describes, inter alia, fusion polypeptides comprising a SARS-CoV-2 Spike polypeptide fragment comprising at least a portion of the N-terminal domain, domains CD1, RBM, and CD2, and at least a portion of CTD1, wherein the N- or C-terminus of the Spike polypeptide fragment is fused to a heterologous N- or C-terminal tag comprising at least two, at least three, or at least four amino acids, as well as polynucleotides and vectors expressing such fusion polypeptides, pharmaceutical compositions comprising the polypeptides or polynucleotides encoding them, host cells for their production, and methods of using such pharmaceutical compositions as vaccines or for generation of antibodies.
Claims54
A fusion polypeptide comprising a SARS-CoV-2 Spike polypeptide fragment comprising at least a portion of the N-terminal domain, domains CD1, RBM, and CD2, and at least a portion of CTD1, wherein the N- or C-terminus of the Spike polypeptide fragment is fused to a heterologous N- or C-terminal tag comprising at least two, at least three, or at least four amino acids.
A fusion polypeptide comprising a SARS-CoV-2 Spike polypeptide fragment comprising at least a portion of the N-terminal domain, domains CD1, RBM, and CD2, and at least a portion of each of NT and CTD1, wherein the N- or C-terminus of the Spike polypeptide fragment is fused to a heterologous N- or C-terminal tag comprising at least two, at least three, or at least four amino acids, wherein the N- and C-terminal residues of the Spike polypeptide fragment are comprised within an antiparallel beta-sheet.
A fusion polypeptide comprising a Spike polypeptide fragment comprising the amino acid sequence of residues 316-594 of SEQ ID NO:
- 1 or comprising an amino acid sequence of a Spike polypeptide fragment that aligns with residues 316-594 of SEQ ID NO:
- 1, wherein the N- or C-terminus of the Spike polypeptide fragment is fused to a heterologous N- or C-terminal tag comprising at least two, at least three, or at least four amino acids.
Dependencies are inferred from the claim text.